Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
作者信息
Mazza Mario Gennaro, Vai Benedetta, De Picker Livia, Benedetti Francesco, Zanardi Raffaella
机构信息
Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.
出版信息
Drugs. 2022 Feb;82(3):349-351. doi: 10.1007/s40265-022-01682-7. Epub 2022 Feb 12.
Abstract
摘要
相似文献
1
Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".评论：“氟伏沙明用于新型冠状病毒2型感染的早期治疗：当前证据综述”
Drugs. 2022 Feb;82(3):349-351. doi: 10.1007/s40265-022-01682-7. Epub 2022 Feb 12.
2
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
3
Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".作者对马扎等人的回复：“氟伏沙明用于早期治疗新型冠状病毒2型感染：当前证据综述”
Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.
4
Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase.氟伏沙明抗新型冠状病毒肺炎的作用可能由内皮型一氧化氮合酶介导。
Pharmacopsychiatry. 2022 Jan;55(1):57. doi: 10.1055/a-1641-0357. Epub 2021 Sep 23.
5
Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.氟伏沙明用于非住院急性新冠肺炎感染患者及在安慰剂对照试验中降低住院率、机械通气率和死亡率方面缺乏疗效：一项系统评价和荟萃分析
Am J Ther. 2022;29(3):e298-e304. doi: 10.1097/MJT.0000000000001496. Epub 2022 Mar 31.
6
Fluvoxamine for COVID-19?氟伏沙明用于治疗新冠病毒肺炎？
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.
7
Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure.氟伏沙明用于急性新冠病毒感染：假设薄弱，注定失败。
Am J Ther. 2022;29(3):e342-e343. doi: 10.1097/MJT.0000000000001502. Epub 2022 Mar 29.
8
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
9
Fluvoxamine for the treatment of COVID-19.氟伏沙明用于治疗新型冠状病毒肺炎。
Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1.
10
Fluvoxamine for the treatment of COVID-19.氟伏沙明用于治疗COVID-19。
Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1.
引用本文的文献
1
Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".作者对马扎等人的回复：“氟伏沙明用于早期治疗新型冠状病毒2型感染：当前证据综述”
Drugs. 2022 Feb;82(3):353-354. doi: 10.1007/s40265-022-01681-8. Epub 2022 Feb 12.
本文引用的文献
1
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
2
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
3
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.COVID 后抑郁中对选择性 5-羟色胺再摄取抑制剂的快速反应。
Eur Neuropsychopharmacol. 2022 Jan;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 9.
4
Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review.COVID-19 相关的精神和神经精神后遗症 - 一项系统性综述。
Brain Behav Immun. 2021 Oct;97:328-348. doi: 10.1016/j.bbi.2021.07.018. Epub 2021 Jul 30.
5
Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis.心境障碍与 COVID-19 感染、住院和死亡风险的关联：系统评价和荟萃分析。
JAMA Psychiatry. 2021 Oct 1;78(10):1079-1091. doi: 10.1001/jamapsychiatry.2021.1818.
6
Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.精神障碍与 COVID-19 相关死亡率、住院和重症监护病房入院风险：系统评价和荟萃分析。
Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17.
7
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.氟伏沙明早期治疗冠状病毒病19的前瞻性队列研究。
Open Forum Infect Dis. 2021 Feb 1;8(2):ofab050. doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
8
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.氟伏沙明对比安慰剂在伴有症状的 COVID-19 门诊患者中的临床恶化：一项随机临床试验。
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
9
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?细胞因子阻断能否预防新冠病毒感染康复者患抑郁症？
J Neuroimmune Pharmacol. 2021 Mar;16(1):1-3. doi: 10.1007/s11481-020-09966-z. Epub 2020 Oct 26.
10
Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors.COVID-19 幸存者的焦虑和抑郁：炎症和临床预测因子的作用。
Brain Behav Immun. 2020 Oct;89:594-600. doi: 10.1016/j.bbi.2020.07.037. Epub 2020 Jul 30.
Zotero 插件